Drugs Containing Excipient (Inactive Ingredient) ACESULFAME POTASSIUM

Branded drugs containing ACESULFAME POTASSIUM excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Haleon US Holdings LLC	NICORETTE	nicotine polacrilex	0135-0241	ACESULFAME POTASSIUM
Haleon US Holdings LLC	NICORETTE	nicotine polacrilex	0135-0474	ACESULFAME POTASSIUM
Haleon US Holdings LLC	NICORETTE	nicotine polacrilex	0135-0508	ACESULFAME POTASSIUM
Haleon US Holdings LLC	NICORETTE	nicotine polacrilex	0135-0625	ACESULFAME POTASSIUM
Haleon US Holdings LLC	NICORETTE	nicotine polacrilex	0135-2800	ACESULFAME POTASSIUM

Generic drugs containing ACESULFAME POTASSIUM excipient

Company	Ingredient	NDC	Excipient
L Perrigo Company	nicotine polacrilex	0113-0029	ACESULFAME POTASSIUM
L Perrigo Company	nicotine polacrilex	0113-0053	ACESULFAME POTASSIUM
L Perrigo Company	loperamide hydrochloride, simethicone	0113-0087	ACESULFAME POTASSIUM
L Perrigo Company	nicotine polacrilex	0113-0170	ACESULFAME POTASSIUM
L Perrigo Company	nicotine polacrilex	0113-0206	ACESULFAME POTASSIUM

Acesulfame Potassium Excipient Market Dynamics and Financial Trajectory

Last updated: August 5, 2026

Acesulfame potassium, also known as acesulfame K or Ace-K, is a high-intensity sweetener used as an inactive ingredient in oral pharmaceutical products. Its pharmaceutical market is smaller than its food and beverage market, but it benefits from low usage levels, high sweetness, strong thermal stability, and broad regulatory acceptance. The financial outlook is stable rather than high-growth: demand is tied primarily to oral dosage-form volumes, while pricing remains exposed to Asian production capacity and commodity-style competition.

What is the pharmaceutical role of acesulfame potassium?

Acesulfame potassium is a synthetic, non-nutritive sweetener with approximately 200 times the sweetness of sucrose. In pharmaceutical products, it is used to improve palatability rather than to provide therapeutic activity.

Typical applications include:

Pharmaceutical format	Role of acesulfame potassium
Chewable tablets	Masks bitterness and improves patient acceptance
Orally disintegrating tablets	Provides rapid sweetness with low mass contribution
Oral powders and granules	Improves taste after reconstitution
Syrups and oral solutions	Sweetens pediatric and liquid formulations
Effervescent products	Supports palatability in acidic or flavored systems
Combination products	Reduces bitterness from active pharmaceutical ingredients

Acesulfame potassium is particularly useful where formulators need a sweetener that contributes little bulk. It is water-soluble, heat-stable and compatible with many solid and liquid oral formulations. Its intense sweetness allows lower inclusion levels than sucrose, dextrose, sorbitol or mannitol.

The ingredient does not have a therapeutic indication, National Drug Code market or standalone FDA drug approval. Its commercial value is derived from use as an excipient in finished pharmaceutical products.

What is the FDA regulatory status of acesulfame potassium?

The FDA regulates acesulfame potassium primarily as a food additive and recognizes its use as an inactive pharmaceutical ingredient. FDA regulations list acesulfame potassium under 21 C.F.R. § 172.800, subject to specified conditions of use [1].

The core regulatory facts are:

Regulatory item	Status
FDA food-additive regulation	21 C.F.R. § 172.800
FDA status in pharmaceutical products	Inactive ingredient
FDA acceptable daily intake	15 mg/kg body weight per day
Primary pharmaceutical route	Oral
FDA Orange Book listing	No standalone listing
FDA exclusivity	None as an excipient
Prescription-drug approval	Not applicable
Regulatory function	Sweetener and taste-masking agent

The FDA has permitted acesulfame potassium in a widening range of food and beverage applications since its initial approvals in the late 1980s. FDA safety reviews have concluded that authorized uses do not present a safety concern at permitted exposure levels [2].

The Joint FAO/WHO Expert Committee on Food Additives established an acceptable daily intake of up to 15 mg/kg body weight [3]. The European Food Safety Authority applies an acceptable daily intake of 9 mg/kg body weight per day for the European Union [4]. The difference does not generally prevent use in pharmaceutical formulations because excipient quantities are normally small relative to food exposure.

What pharmacopeial and quality standards apply to acesulfame potassium?

Pharmaceutical buyers generally qualify acesulfame potassium against a compendial monograph, supplier specification or both. The relevant quality controls can include:

• Identification and assay
• Water content
• Residual solvents
• Related substances
• Heavy metals or elemental impurities
• Microbial limits
• Particle-size distribution
• Bulk density
• Residual inorganic salts
• Stability under expected storage conditions

The United States Pharmacopeia-National Formulary and European Pharmacopoeia are important commercial quality references for pharmaceutical-grade material. A manufacturer supplying regulated drug markets normally must provide a certificate of analysis, change-control commitments, manufacturing-site information and supporting impurity data.

The principal technical risk is not the sweetening function. It is batch-to-batch consistency and control of process-related impurities. Customers may require tighter specifications than those used for food-grade material, creating a price distinction between pharmaceutical-grade and standard food-grade product.

How large is the acesulfame potassium pharmaceutical market?

There is no reliable public financial disclosure for pharmaceutical-grade acesulfame potassium as a standalone market. Producers generally report it within broader sweetener, food-ingredient or specialty-ingredient businesses. Public market reports also use different definitions, often combining acesulfame potassium with sucralose, aspartame, saccharin, steviol glycosides and other high-intensity sweeteners.

The market structure is best described as follows:

Market characteristic	Assessment
Total demand base	Primarily food and beverage
Pharmaceutical share	Minority share of global volume
Pharmaceutical growth driver	Oral liquid, chewable and orally disintegrating products
Pricing model	Contract supply plus spot and distributor sales
Customer concentration	Higher in pharmaceutical supply than in food
Switching cost	Moderate after qualification
Product differentiation	Limited at the molecule level; higher at quality and supply level
Margin profile	Higher for qualified pharmaceutical supply than commodity food supply
Public revenue visibility	Low

Pharmaceutical demand is structurally defensive. Acesulfame potassium is consumed in small quantities per unit, so changes in active pharmaceutical ingredient volumes have a larger effect on the number of formulations than on the cost of each finished product. The excipient usually represents a negligible share of the finished drug's cost.

What factors are driving acesulfame potassium demand?

The strongest demand drivers are formulation convenience, pediatric palatability and growth in patient-friendly oral dosage forms.

Oral dosage-form growth

Orally disintegrating tablets, chewables and oral liquids remain important where swallowing difficulty, pediatric administration or rapid disintegration affects product selection. Acesulfame potassium can be incorporated into low-dose formulations without materially increasing tablet size or viscosity.

Taste masking

Many active pharmaceutical ingredients are bitter, metallic or otherwise unpleasant. Acesulfame potassium is often used with flavors, polymers, sweeteners and bitterness-blocking agents. It is rarely the only taste-masking tool in a difficult formulation.

Sugar reduction

Pharmaceutical companies increasingly use intense sweeteners to reduce sucrose and caloric content in pediatric syrups, supplements and consumer-health products. Acesulfame potassium can also be combined with sucralose or polyols to improve taste balance.

Thermal and formulation stability

The ingredient is suitable for products exposed to heat during processing or storage. Its stability profile supports use in tablets, powders and selected liquid systems, although pH, microbial control and compatibility must be evaluated for each formulation.

Global regulatory acceptance

Acceptance in the United States, European Union and international food-safety frameworks reduces the need for country-specific toxicology work. Pharmaceutical sponsors still need product-specific excipient assessment, but the global safety record supports procurement and formulation reuse.

What limits the financial growth of the acesulfame potassium market?

The pharmaceutical opportunity is constrained by four factors.

First, the ingredient has low value per dose. Acesulfame potassium can improve patient acceptance without materially increasing the selling price of a drug, but that also limits the absolute revenue available to the excipient supplier.

Second, formulations can substitute other sweeteners. Sucralose, aspartame, saccharin, steviol glycosides, sodium cyclamate where permitted, and polyols can compete for the same taste-masking function. Selection depends on taste profile, stability, regulatory status and compatibility.

Third, customers can qualify multiple suppliers. Once a drug manufacturer has validated equivalent material, price and supply reliability become major purchasing factors.

Fourth, the largest demand pool is outside pharmaceuticals. Food and beverage producers can influence capacity utilization, pricing and investment even when pharmaceutical demand is stable.

Who manufactures and supplies pharmaceutical-grade acesulfame potassium?

The supplier base includes established specialty-ingredient companies and Asian manufacturers. Nutrinova is associated with the Sunett brand of acesulfame potassium. Chinese producers also supply global food and pharmaceutical markets, including manufacturers such as Anhui Jinhe Industrial Co., Ltd. The commercial supplier set changes through capacity additions, ownership changes, distributor arrangements and customer qualification decisions.

A buyer evaluating a supplier should assess:

1. Manufacturing-site inspection history.
2. GMP controls for pharmaceutical-grade production.
3. Regulatory support for United States, European and Asian markets.
4. Change-notification periods.
5. Dual-sourcing capability.
6. Residual-solvent and impurity controls.
7. Capacity outside China.
8. Lead times and inventory policy.
9. Documentation for excipient risk assessment.
10. Ability to support pediatric and liquid formulations.

The largest competitive advantage is usually supply reliability and documentation rather than molecular differentiation.

What is the financial trajectory for acesulfame potassium suppliers?

No major producer appears to report acesulfame potassium revenue as a separate public segment. Celanese has historically included Nutrinova and related food ingredients within broader reporting structures, limiting direct analysis of product-level sales [5]. Private and regional manufacturers generally do not disclose product-level revenue, volume or margins.

The financial trajectory can be divided into three periods:

Period	Market condition	Financial effect
2020-2021	Supply-chain disruption and logistics pressure	Higher freight, inventory and working-capital costs
2022-2023	Input-cost inflation and normalization of logistics	Price volatility and margin pressure
2024 onward	More normalized supply and competitive capacity	Lower pricing power, steadier volume growth

The base-case outlook is low-single-digit volume growth in pharmaceutical applications, with revenue growth dependent on price retention and product mix. Pharmaceutical-grade material should maintain better pricing than commodity food-grade material because customers incur qualification costs when changing suppliers.

Margin expansion would require one of three developments:

• Higher pharmaceutical-grade mix.
• Long-term contracts with large drug manufacturers.
• Greater supply concentration or capacity discipline.

Margin compression would result from new Asian capacity, distributor destocking, lower food-and-beverage pricing or successful substitution by other sweeteners.

How strong is the patent estate for acesulfame potassium?

Acesulfame potassium has no meaningful modern composition-of-matter patent barrier. The original discovery and manufacturing patents date back several decades and are expired. The molecule is therefore available for manufacture by qualified suppliers, subject to regulatory, quality and process requirements.

The current protection profile is:

IP category	Commercial position
Core molecule	Public-domain and long expired
Foundational synthesis patents	Expired
Formulation patents	Possible, but generally cover a specific drug composition rather than acesulfame potassium itself
Manufacturing process patents	Potentially relevant if narrow, current and enforceable
Supplier trade secrets	Relevant to yield, purification and impurity control
Brand rights	Possible for trademarks such as Sunett
Pharmaceutical exclusivity	None for the excipient itself

The primary barriers are manufacturing know-how, regulatory qualification, customer audits, analytical methods and supply-chain reliability. These are practical barriers, not durable exclusivity rights.

What patent litigation, Paragraph IV challenges and settlements affect acesulfame potassium?

Acesulfame potassium itself does not have an Orange Book patent estate. It is not a listed drug product, so it does not generate ordinary Paragraph IV litigation, Hatch-Waxman settlements or generic-entry litigation.

Patent disputes can still involve a drug product that uses acesulfame potassium. In those cases, the relevant patents may cover:

• The active pharmaceutical ingredient.
• A taste-masked formulation.
• An orally disintegrating tablet.
• A liquid formulation.
• A method of treating a disease.
• A specific combination of sweetener, flavor and active ingredient.

Acesulfame potassium would normally be an ingredient inside the claimed formulation, not the source of exclusivity. A generic applicant could challenge a formulation patent that recites acesulfame potassium, but the challenge would concern the drug product's claim scope rather than ownership of the excipient.

When does acesulfame potassium lose exclusivity?

Acesulfame potassium has already lost molecule-level exclusivity. There is no pending FDA exclusivity period, patent cliff or biosimilar event associated with the excipient.

Exclusivity question	Answer
Composition patent expiration	Historical patents expired
FDA new chemical entity exclusivity	Not applicable
Orphan-drug exclusivity	Not applicable
Pediatric exclusivity	Not applicable
Orange Book patent expiry	No standalone listing
Biosimilar exclusivity	Not applicable
Generic launch date	Already available from multiple suppliers

The relevant commercial risk is supplier substitution, not generic entry against a protected molecule.

What manufacturing and IP barriers affect market entry?

Manufacturing acesulfame potassium requires chemical synthesis, purification, crystallization and quality control. The exact process is commercially important because impurities, color, particle characteristics and yield can affect customer acceptance.

A new supplier faces several barriers:

• Capital investment in chemical manufacturing.
• Process safety and environmental controls.
• Qualification against customer specifications.
• Regulatory support across multiple jurisdictions.
• Demonstration of consistent impurity profiles.
• Reliable availability of starting materials.
• Multi-year customer validation cycles.
• Technical support for formulation scientists.

Trade secrets may protect process economics, but they do not prevent competitors from producing the molecule through an alternative route. The strongest protection is operational execution combined with customer qualification.

How does acesulfame potassium compare with competing pharmaceutical sweeteners?

Excipient	Relative strength	Main limitation
Acesulfame potassium	Intense sweetness, low dose, heat stability	Bitter aftertaste at higher levels
Sucralose	Strong taste profile and broad acceptance	Higher cost in some markets
Aspartame	Good sugar-like taste	Phenylalanine labeling and lower heat stability
Saccharin sodium	Low cost and strong sweetness	Aftertaste and regulatory preferences
Stevia glycosides	Plant-derived positioning	Taste variability and formulation complexity
Sorbitol or mannitol	Sweetness plus bulk and mouthfeel	Higher dose and caloric or gastrointestinal considerations

Acesulfame potassium is most competitive where low dosage, cost control and processing stability matter. Sucralose may be preferred where taste quality is more important than unit cost. Polyols are more useful when the formulation requires bulk, cooling sensation or tablet mass.

What generic launch risks exist for drugs containing acesulfame potassium?

For a finished pharmaceutical product, acesulfame potassium creates little standalone generic-entry risk. The risk depends on the drug's active ingredient, listed patents, formulation claims and regulatory pathway.

A generic applicant may use acesulfame potassium if the reference product's inactive ingredients are not protected and the proposed formulation meets applicable requirements. A formulation patent could create a barrier if it requires a specific ratio, dosage form, particle structure or combination of excipients. Such patents must be analyzed at the drug-product level.

For drug manufacturers, the main commercial risk is reverse: a generic competitor can often reproduce the taste-masking function with acesulfame potassium or another sweetener. The excipient rarely supports meaningful product differentiation on its own.

What is the geographic coverage of the acesulfame potassium market?

The United States, European Union and China are the main regulatory and manufacturing reference markets. India, Southeast Asia, Latin America and the Middle East are important growth markets for oral medicines, consumer health products and processed foods.

Regional considerations include:

• United States: FDA food-additive regulation and drug-excipient qualification.
• European Union: E950 designation and EFSA exposure limits.
• China: domestic food and pharmaceutical standards, with exports subject to destination-market requirements.
• India: growing oral-liquid and generic-drug manufacturing base.
• Japan and South Korea: demanding quality and documentation requirements.
• Emerging markets: increasing use of lower-cost oral dosage forms and pediatric products.

Global suppliers benefit from regulatory dossiers that can be reused across markets. Local registration, language requirements and customer audits still create execution costs.

Key Takeaways

• Acesulfame potassium is an established oral pharmaceutical sweetener, not an active drug ingredient.
• Its pharmaceutical demand is stable but smaller than food and beverage demand.
• Growth is linked to chewables, orally disintegrating tablets, pediatric medicines and oral liquids.
• FDA regulation is established under 21 C.F.R. § 172.800; FDA's acceptable daily intake is 15 mg/kg body weight per day.
• The European Union uses an acceptable daily intake of 9 mg/kg body weight per day.
• The molecule has no current composition-of-matter exclusivity or standalone Orange Book listing.
• Paragraph IV litigation, biosimilar competition and FDA exclusivity do not apply to the excipient itself.
• Supplier economics depend on scale, process yield, pharmaceutical-grade qualification and supply reliability.
• The main financial risk is commodity-style price competition from Asian capacity.
• The main commercial opportunity is higher-margin, qualified pharmaceutical supply rather than molecule-level IP protection.

FAQs

Is acesulfame potassium safe in pharmaceutical formulations?

Regulators including the FDA, EFSA and JECFA have evaluated acesulfame potassium and established acceptable daily intake levels. Pharmaceutical use is normally low relative to total dietary exposure.

Does acesulfame potassium require an FDA DMF?

An FDA Drug Master File is not automatically required for every excipient. A supplier may provide regulatory information through a DMF, customer dossier or direct documentation package, depending on the sponsor's filing strategy and product risk assessment.

Can acesulfame potassium be used in pediatric medicines?

Yes. It is used in pediatric oral liquids, chewables and orally disintegrating products, subject to product-specific safety, exposure, taste and formulation assessments.

Is pharmaceutical-grade acesulfame potassium more expensive than food-grade material?

It can command a premium because of tighter specifications, documentation, audits, testing and change-control requirements. The premium varies by supplier, volume, region and contract terms.

Can a pharmaceutical company switch from acesulfame potassium to sucralose?

A switch may require formulation development, taste testing, stability studies, analytical review and regulatory assessment. The operational burden depends on whether the change affects composition, labeling, product performance or approved regulatory filings.

References

1. U.S. Food and Drug Administration. (n.d.). 21 C.F.R. § 172.800: Acesulfame potassium. Electronic Code of Federal Regulations. https://www.ecfr.gov/current/title-21/section-172.800

2. U.S. Food and Drug Administration. (n.d.). Additional information about high-intensity sweeteners permitted for use in food in the United States. https://www.fda.gov/food/food-additives-petitions/high-intensity-sweeteners

3. Joint FAO/WHO Expert Committee on Food Additives. (1991). Evaluation of certain food additives and contaminants: Thirty-seventh report of JECFA. World Health Organization. https://apps.who.int/iris/

4. European Food Safety Authority. (2011). Scientific opinion on the re-evaluation of acesulfame K as a food additive. EFSA Journal, 9(6), 2177. https://doi.org/10.2903/j.efsa.2011.2177

5. Celanese Corporation. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. https://investors.celanese.com/financial-information/annual-reports-and-proxy-statements/default.aspx